Key terms
About CDTX
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CDTX news
May 17
2:01am ET
Cidara Therapeutics Inc. Hits Snag: Delayed 10-K Filing Complicates Capital Raising Efforts
May 16
6:26am ET
Buy Rating Justified by Cidara Therapeutics’ Upcoming Clinical Trials and Expanding Oncology Pipeline
Apr 26
8:03am ET
Cidara Therapeutics announces presentations on CD388 data
Apr 25
9:48am ET
Cidara Therapeutics rating placed under review at H.C. Wainwright
Apr 25
6:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Apr 24
4:25pm ET
Cidara Therapeutics Refocuses Strategy with Asset Sale
Apr 24
4:24pm ET
Cidara Therapeutics: Strategic Partnerships and Governance Changes
Apr 24
4:13pm ET
Cidara Therapeutics reacquires rights to CD388 from Johnson & Johnson for $85M
Apr 24
4:03pm ET
Cidara Therapeutics divests rezafungin to Mundipharma
Apr 24
10:53am ET
Biotech Alert: Searches spiking for these stocks today
Apr 24
2:00am ET
Cidara Therapeutics’ Restatement Woes: Costs, Distractions, and Investor Confidence on the Line
Apr 23
7:50pm ET
Cidara Therapeutics trading halted, news pending
Apr 22
5:13pm ET
Cidara Therapeutics reports Q4 EPS (4c), consensus (10c)
Apr 22
5:08pm ET
Cidara Therapeutics discloses Nasdaq listing deficiency notice
Apr 22
8:55am ET
Cidara Therapeutics announces 1-for-20 reverse stock split
Apr 08
10:45am ET
Buy Rating Affirmed for Cidara Therapeutics Amid Promising Oncology Program Developments
May 15
2:40pm ET
ROSEN, A LEADING NATIONAL FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
May 12
1:30pm ET
CDTX Equity Alert: ROSEN, Leading Investor Counsel, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
CDTX Financials
Key terms
Ad Feedback
CDTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CDTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range